Citizens Financial Group Inc RI lessened its position in Zoetis Inc. (NYSE:ZTS) by 39.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,371 shares of the company’s stock after selling 2,173 shares during the quarter. Citizens Financial Group Inc RI’s holdings in Zoetis were worth $210,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its position in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after acquiring an additional 230 shares in the last quarter. Assetmark Inc. lifted its position in shares of Zoetis by 4.6% in the 1st quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after acquiring an additional 85 shares in the last quarter. Guardian Life Insurance Co. of America lifted its position in shares of Zoetis by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after acquiring an additional 13 shares in the last quarter. Point72 Asia Hong Kong Ltd purchased a new stake in shares of Zoetis in the 1st quarter valued at approximately $111,000. Finally, Almanack Investment Partners LLC. purchased a new stake in shares of Zoetis in the 2nd quarter valued at approximately $119,000. Institutional investors and hedge funds own 93.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zoetis Inc. (ZTS) Shares Sold by Citizens Financial Group Inc RI” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/09/14/zoetis-inc-zts-shares-sold-by-citizens-financial-group-inc-ri.html.

ZTS has been the subject of several research analyst reports. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Hilliard Lyons initiated coverage on shares of Zoetis in a research report on Tuesday, June 20th. They issued a “buy” rating and a $77.00 price target for the company. Deutsche Bank AG reiterated a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Argus reiterated a “buy” rating and issued a $69.00 price objective (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, July 21st. One analyst has rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Zoetis currently has an average rating of “Buy” and a consensus price target of $65.44.

Zoetis Inc. (NYSE:ZTS) opened at 65.035 on Thursday. The company has a 50 day moving average of $61.99 and a 200 day moving average of $59.22. The firm has a market capitalization of $31.81 billion, a P/E ratio of 36.764 and a beta of 1.02. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $65.50.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.53. The company had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.49 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post $2.34 earnings per share for the current year.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.